Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Narratives
Your Valuation
🌎 Global
Global
United States
Australia
United Kingdom
Canada
India
China
Argentina
Austria
Bahrain
Bangladesh
Belgium
Bermuda
Botswana
Brazil
Bulgaria
Chile
Colombia
Croatia
Cyprus
Czech Republic
Denmark
Egypt
Estonia
Finland
France
Germany
Ghana
Greece
Hong Kong
Hungary
Iceland
Indonesia
Ireland
Israel
Italy
Ivory Coast
Jamaica
Japan
Jordan
Kenya
Kuwait
Latvia
Lithuania
Luxembourg
Malawi
Malaysia
Malta
Mauritius
Mexico
Morocco
Namibia
Netherlands
New Zealand
Nigeria
Norway
Oman
Pakistan
Palestinian Authority
Peru
Philippines
Poland
Portugal
Qatar
Romania
Russia
Saudi Arabia
Serbia
Singapore
Slovakia
Slovenia
South Africa
South Korea
Spain
Sri Lanka
Sweden
Switzerland
Taiwan
Tanzania
Thailand
Trinidad & Tobago
Tunisia
Turkey
Uganda
Ukraine
United Arab Emirates
Venezuela
Vietnam
Zambia
Zimbabwe
Create a narrative
Global Community
Our community narratives are driven by numbers and valuation.
Create a narrative
Community Investing Ideas
Global Weekly Picks
GXAI
Gaxos.ai
Sponsored
content by Gaxos.ai
JO
Jolt_Communications
Community Contributor
Gaxos.ai: Early-Stage AI Innovator in Gaming & Health
Key Takeaways Dual AI focus – Gaxos.ai builds AI-powered tools for game developers (via Unity integrations) and AI-driven health services under its RNK Health brand. First signs of commercial traction – After years of development, the company reported ~$194k in H1 2025 revenue, mainly from wellness pilot programs.
View narrative
US$2.21
FV
5.9% undervalued
intrinsic discount
119.00%
Revenue growth p.a.
Set Fair Value
1
users have liked this narrative
1
users have commented on this narrative
24
users have followed this narrative
Updated
narrative
Microsoft
PI
PicaCoder
Community Contributor
After the AI Party: A Sobering Look at Microsoft's Future
The world has been captivated by the artificial intelligence boom, and no company has ridden the wave of investor enthusiasm quite like Microsoft. Buoyed by its strategic partnership with OpenAI and the integration of AI across its product ecosystem, the company's valuation has soared to unprecedented heights.
View narrative
US$500.00
FV
1.4% overvalued
intrinsic discount
6.75%
Revenue growth p.a.
Set Fair Value
20
users have liked this narrative
9
users have commented on this narrative
25
users have followed this narrative
11 days ago
author updated this narrative
Amazon.com
ZW
Zwfis
Community Contributor
Amazon's Future Rises as Stock Price Falls: A Long-Term Investment Vision
Amazon is a stock I am very interested in right now especially with the recent price drops that it has been experiencing since its 2Q25 results. A summary of Amazon as stated by Fiscal.ai: "Amazon.com, Inc.
View narrative
US$234.75
FV
2.5% undervalued
intrinsic discount
13.60%
Revenue growth p.a.
Set Fair Value
18
users have liked this narrative
7
users have commented on this narrative
22
users have followed this narrative
New
narrative
Verve Group
TI
TibiT
Community Contributor
Verve Group: A Tale of Three Futures
Verve Group stands at a critical juncture. After a history of explosive growth, the company has been hit by significant operational headwinds, primarily the difficult and costly migration to a unified technology platform and unfavorable currency exchange rates.
View narrative
€4.02
FV
44.5% undervalued
intrinsic discount
8.50%
Revenue growth p.a.
Set Fair Value
3
users have liked this narrative
0
users have commented on this narrative
15
users have followed this narrative
Updated
narrative
All companies
Popular
Undervalued
Overvalued
Load previous narratives
Transocean
AN
AnalystLowTarget
Consensus Narrative from 13 Analysts
Rising Regulatory Costs And High Debt Will Undermine Offshore Profitability
Key Takeaways Accelerating renewables adoption and regulatory pressure threaten long-term demand, margins, and revenue growth for Transocean's offshore drilling business. High debt, aging fleet, and increasing competition constrain financial flexibility and may significantly impact future profitability.
View narrative
US$2.50
FV
21.6% overvalued
intrinsic discount
-1.40%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
New
narrative
LifeMD
AN
AnalystLowTarget
Consensus Narrative from 8 Analysts
Intensifying Regulation And Churn Will Limit Prospects While Stability Emerges
Key Takeaways Regulatory scrutiny, high refund rates, and customer acquisition challenges threaten margins, profitability, and the sustainability of revenue growth. High patient churn and intensifying competition may offset operational efficiencies and limit long-term earnings and margin gains.
View narrative
US$8.00
FV
20.9% undervalued
intrinsic discount
13.00%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
New
narrative
Invivyd
AN
AnalystLowTarget
Consensus Narrative from 2 Analysts
Regulatory Risks And Competition Will Impede Gains But Yield Promise
Key Takeaways Heavy reliance on emergency authorizations, regulatory uncertainties, and a narrow late-stage pipeline threaten Invivyd's long-term revenue stability and growth prospects. Heightened pricing pressures, high R&D costs, and formidable competition may erode profitability despite strong product demand and innovative advances in antibody engineering.
View narrative
US$3.00
FV
82.7% undervalued
intrinsic discount
94.77%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
New
narrative
Core Scientific
AN
AnalystLowTarget
Consensus Narrative from 11 Analysts
Concentrated Contracts Will Threaten Data Center Stability Yet Uncover Upside
Key Takeaways High client and revenue concentration plus heavy capital needs expose the company to execution risks, margin pressure, and profitability threats if any major deal falters. Transition away from mining and reliance on favorable energy contracts create vulnerability to market, regulatory, and operational headwinds that could hamper utilization and growth.
View narrative
US$15.00
FV
9.7% undervalued
intrinsic discount
56.30%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
New
narrative
Neuren Pharmaceuticals
AN
AnalystLowTarget
Consensus Narrative from 8 Analysts
US And EU Regulation Will Erode Prospects Yet Offer Hope
Key Takeaways Heavy reliance on DAYBUE and single-indication focus exposes Neuren to significant revenue concentration and regulatory risk. Growing competition, regulatory pressures, and reimbursement scrutiny threaten future margins and the company's long-term growth potential.
View narrative
AU$18.60
FV
7.7% undervalued
intrinsic discount
-24.13%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
New
narrative
Iluka Resources
AN
AnalystLowTarget
Consensus Narrative from 11 Analysts
Rising Costs And Depleting Reserves Will Erode Long-Term Profitability
Key Takeaways Increased regulatory costs and resource depletion are expected to erode margins and weigh on long-term profitability and cash flow. Structural changes in material demand and concentrated customer exposure heighten risks to revenue growth and project returns.
View narrative
AU$5.30
FV
14.7% overvalued
intrinsic discount
10.23%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
New
narrative
Geron
AN
AnalystLowTarget
Consensus Narrative from 8 Analysts
Drug Pricing Controls And Approval Delays Will Curb Viability
Key Takeaways Overdependence on a single product and rising competition threaten revenue stability and long-term market share. Stricter global pricing, regulatory pressures, and challenging funding conditions may constrain growth, margins, and future innovation.
View narrative
US$1.00
FV
46.0% overvalued
intrinsic discount
37.72%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
New
narrative
Root
AN
AnalystLowTarget
Consensus Narrative from 5 Analysts
Privacy Concerns And Competition Will Harm Pricing Yet Enable Recovery
Key Takeaways Heavy dependence on data-driven, AI-powered models and digital adoption creates growth potential, but also exposes Root to regulatory risks and competitive pressures that threaten differentiation. Limited scale and exposure to external volatility make earnings unpredictable, while unproven models and rising claims costs could undermine profitability despite technological investments.
View narrative
US$105.00
FV
13.3% undervalued
intrinsic discount
8.90%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
New
narrative
Life360
AN
AnalystLowTarget
Consensus Narrative from 9 Analysts
Privacy Regulations And Rival Platforms Will Erode Value
Key Takeaways Growing privacy regulations and consumer concerns threaten Life360's ability to monetize data, jeopardizing ad revenue, subscription growth, and profitability. Competition from major device makers and rising regulatory risks erode differentiation, driving down margins and weakening Life360's long-term user engagement.
View narrative
AU$27.32
FV
65.0% overvalued
intrinsic discount
17.93%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
New
narrative
Value any company in seconds
Popular companies